SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Natco Pharma informs about newspaper advertisement

13 Aug 2021 Evaluate
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, Natco Pharma has informed that it enclosed the copies of the newspaper advertisement regarding Un-audited Financial Results of the Company for quarter ended 30th June, 2021 and Notice of Declaration of Interim Dividend and Record Date. The advertisements are as appeared on 13th August 2021 in Business Standard (English) and Nava Telangana (Telugu).

The above information is a part of company’s filings submitted to BSE.

Natco Pharma Share Price

983.55 22.10 (2.30%)
10-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1935.25
Dr. Reddys Labs. 1245.50
Cipla 1438.75
Zydus Lifesciences 1150.50
Lupin 2496.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: